{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:09:06Z","timestamp":1792807746994,"version":"4.5.0"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      This study compared the effectiveness and safety of direct oral anticoagulants (DOACs) versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) and intermediate stroke risk, defined by a CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      -VASc score of 1 in men and 2 in women.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study used Korean Health Insurance Review and Assessment Service claims data. Patients diagnosed with NVAF between January 1, 2017, and December 31, 2019, who initiated DOACs or aspirin, were included. Eligibility was restricted by CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      -VASc score, and patients were matched by age and sex to reduce confounding. The observation period extended until November 30, 2021. The primary outcomes were the incidence of ischemic stroke (effectiveness) and major bleeding events (safety).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 2234 patients included, 977 (43.7%) were treated with DOACs, and 1257 (56.3%) received aspirin. After matching, no statistically significant differences were observed between the DOAC and aspirin groups in ischemic stroke incidence (1.46 vs 0.92 per 100 person-years,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.060) or major bleeding events (2.26 vs 2.10 per 100 person-years,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.100). Notably, rheumatic disease was associated with an increased risk of ischemic stroke, while liver disease was linked to a higher risk of major bleeding.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In NVAF patients with intermediate stroke risk, no statistically significant differences were observed in ischemic stroke or major bleeding between DOACs and aspirin. These results should not be interpreted as therapeutic equivalence but highlight the need for further real-world research, particularly in Asian populations, to inform optimal antithrombotic strategies in this subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10760296261416892","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:51:03Z","timestamp":1768931463000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and Safety of Direct Oral Anticoagulants versus Aspirin in Patients with Non-Valvular Atrial Fibrillation and Intermediate Stroke Risk"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7016-5124","authenticated-orcid":false,"given":"Susin","family":"Park","sequence":"first","affiliation":[{"name":"Kyungsung University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-5131","authenticated-orcid":false,"given":"Nam Kyung","family":"Je","sequence":"additional","affiliation":[{"name":"Pusan National University"},{"name":"Pusan National University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.22.8.983"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01236-6"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw233"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"issue":"12","key":"e_1_3_3_8_2","first-page":"1847","article-title":"The 2020 Canadian cardiovascular society\/Canadian heart rhythm society comprehensive guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade JG","unstructured":"Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian cardiovascular society\/Canadian heart rhythm society comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol. 2020 Dec;36(12):1847-1948. https:\/\/doi.org\/10.1016\/j.cjca.2020.09.001","journal-title":"Can J Cardiol"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.07.040"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3904\/kjm.2018.93.2.87.e1"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.5694\/mja18.00646"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176"},{"issue":"21","key":"e_1_3_3_13_2","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the heart rhythm society","volume":"64","author":"January CT","unstructured":"January CT, Wann LS, Alpert JS, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2014 Dec;64(21):e1-e76. https:\/\/doi.org\/10.1016\/j.jacc.2014.03.022","journal-title":"J Am Coll Cardiol."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006186.pub2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(06)68845-4"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91200-2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.14.1513"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2005.08.005"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.05.084"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7215.958"},{"issue":"8899","key":"e_1_3_3_21_2","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study","volume":"343","author":"Investigators SPiAF","year":"1994","unstructured":"Investigators SPiAF. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study. Lancet. 1994;343(8899):687-691.","journal-title":"Lancet."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eux301"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42444-021-00053-9"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-017-0477-3"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/1074248418757010"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.4082\/kjfm.20.0062"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2019.01.024"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy136"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2016.11.033"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2015.45.1.9"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae458"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e1257"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261416892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296261416892","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261416892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:38Z","timestamp":1777385138000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296261416892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"alternative-id":["10.1177\/10760296261416892"],"URL":"https:\/\/doi.org\/10.1177\/10760296261416892","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"10760296261416892"}}